Product Information
XOPENEX HFA 45 MCG INHALER is a brand product labeled by Lupin Pharmaceuticals Inc., priced at $4.9878 per GM under NDC 27437005601. Its NADAC has been published 146 times since Dec 20, 2023.
FDA first approved this application on Mar 11, 2005.
Strength
45 ug/1
Manufacturer
Lupin Pharmaceuticals Inc.NDC
27437005601
Classification
Brand
Dosage Form
AEROSOL, METERED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LEVALBUTEROL TARTRATEApproval Type
New Drug (NDA)
FDA Application
NDA021730FDA Approved
3/11/2005
On Market Since
11/10/2023
Pharmacological Classes
Price Statistics
The NADAC for XOPENEX HFA 45 MCG INHALER has been published 146 times since Dec 20, 2023, and over the history we have for it it has risen 8.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.9878 per GM |
|---|---|
| All-time high | $5.0542 (Jun 10, 2026) |
| All-time low | $4.4395 (Apr 17, 2024) |
| 52-week high | $5.0542 |
| 52-week low | $4.7745 |
| Median price | $4.7877 |
| Average price | $4.7795 |
| Largest weekly change | +5.0% (Aug 28, 2024) |
| Weeks tracked | 146 |
| Tracking since | Dec 20, 2023 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 29% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
levalbuterol tartrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
beta2-Adrenergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of XOPENEX HFA 45 MCG INHALER?
The current National Average Drug Acquisition Cost (NADAC) for XOPENEX HFA 45 MCG INHALER, manufactured by Lupin Pharmaceuticals Inc., is $4.9878 per GM (NDC 27437005601), effective Sep 30, 2026.
How has the price of XOPENEX HFA 45 MCG INHALER changed over time?
Over the history we have for it, the NADAC for XOPENEX HFA 45 MCG INHALER has risen 8.8%. It has been tracked across 146 weekly CMS publications since Dec 20, 2023.
What are the highest and lowest recorded NADAC prices for XOPENEX HFA 45 MCG INHALER?
Since Dec 20, 2023, the NADAC for XOPENEX HFA 45 MCG INHALER has ranged from a low of $4.4395 (Apr 17, 2024) to a high of $5.0542 (Jun 10, 2026), with a median of $4.7877 per GM.
Are there cheaper alternatives to XOPENEX HFA 45 MCG INHALER?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LEVALBUTEROL TAR HFA 45 MCG INH, is $3.5497 per GM — about 29% below XOPENEX HFA 45 MCG INHALER.
Who manufactures XOPENEX HFA 45 MCG INHALER?
XOPENEX HFA 45 MCG INHALER (NDC 27437005601) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a brand product.